Prevention of hormone-related cancers: Prostate cancer

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 368-377

  Parnes, Howard L ^a   Thompson, Ian M ^a   Ford, Leslie G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROSTANOLONE; CYTOCHROME P450 17; FINASTERIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENZYME INHIBITOR;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INHIBITION; ETHNICITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HORMONAL CARCINOGENESIS; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TUMOR BIOPSY; URINE RETENTION; BIOLOGICAL MODEL; BLOOD; GENETIC PREDISPOSITION; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; RISK FACTOR;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MODELS, GENETIC; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 13744251141     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.027     Document Type: Review

References (85)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Sakr WA: Epidemiology of prostate cancer and its precursors. Mod Pathol 20: 10.1038/modpathol.3800074
3. Kramer BS, Brown MI, Prorok PC, et al: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119:914-923, 1993
4. Neal DE, Donovan JL: Prostate cancer: to screen or not to screen? Lancet Oncol 1:17-24, 2000
5. Parnes HL, House MG, Kagan J, et al: Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. J Urol 171: S68-75, 2004
6. Ross RK, Pike MC, Coetzee GA, et al: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497-4504, 1998
7. Montie JE, Pienta KJ: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 43:892-899, 1994
8. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 167:948-952, 2002 (2 pt 2)
9. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
10. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
11. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355:1491-1498, 2002
12. El Sheikh SS, Domin J, Abel P, et al: Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 5:99-109, 2003
13. Wu CP, Gu FL: The prostate in eunuchs. Prog Clin Biol Res 370:249-255, 1991
14. Thompson IM Jr, Kouril M, Klein EA, et al.: The Prostate Cancer Prevention Trial: Current status and lessons learned. Urology 57:230-234, 2001 (4 suppl 1)
15. Civantos F, Soloway MS, Pinto JE: Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 14:22-31, 1996
16. Bostwick DG: Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat Pathol 3:1-16, 1998
17. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015, 2002
18. Noble RL: The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37:1929-1933, 1977
19. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003
20. Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126:1165-1172, 1990
21. Hsing AW: Hormones and prostate cancer: what's next? Epidemiol Rev 23:42-58, 2001
22. Hsing AW, Reichardt JK, Stanczyk FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate 52:213-235, 2002
23. Hryb DJ, Khan MS, Romas NA, et al: The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J Biol Chem 265:6048-6054, 1990
24. Makridakis NM, di Salle E, Reichardt JK: Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 10:407-413, 2000
25. Thigpen AE, Silver RI, Guileyardo JM, et al: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92:903-910, 1993
26. Shirakawa T, Okada H, Acharya B, et al: Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 58:33-40, 2004
27. Lazier CB, Thomas LN, Douglas RC, et al: Dutasteride, the dual Salpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58:130-144, 2004
28. Horton R: Dihydrotestosterone is a peripheral paracrine hormone. J Androl 13:23-27, 1992
29. Horton R, Lobo R: Peripheral androgens and the role of androstanediol glucuronide. Clin Endocrinol Metab 15:293-306, 1986
30. Makridakis NM, Reichardt JK: Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev 23:24-29, 2001
31. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521, 1996
32. Park JJ, Irvine RA, Buchanan G, et al: Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 60:5946-5949, 2000
33. Henderson BE, Bernstein L, Ross RK, et al: The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216-218, 1988
34. Nakata S, Takahashi H, Ohtake N, et al: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7:254-257, 2000
35. Ross RK, Bernstein L, Lobo RA, et al: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887-889, 1992
36. Wu AH, Whittemore AS, Kolonel LN, et al: Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4:735-741, 1995
37. Platz EA, Rimm EV, Willett WC, et al: Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 92: 2009-2017, 2000
38. Shaneyfelt T, Husein R, Bubley G, et al: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847-853, 2000
39. Gann PH, Hennekens CH, Ma J, et al: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118-1126, 1996
40. Eaton NE, Reeves GK, Appleby PN, et al: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80:930-934, 1999
41. Hsing AW, Comstock GW: Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2:27-32, 1993
42. Whitmore W: Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Washingotn DC, US Department of Health and Human Services, 1998
43. Madigan MP, Gao YT, Deng J, et al: CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 107:271-275, 2003
44. Ntais C, Polycarpou A, Tsatsoulis A: Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 149:469-477, 2003
45. Chamberlain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181-3186, 1994
46. Bennett CL, Price DK, Kim S, et al: Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 20:3599-3604, 2002
47. Balic I, Graham ST, Troyer DA, et al: Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 168:2245-2248, 2002
48. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320-3323, 1997
49. Hsing AW, Gao YT, Wu G, et al: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 60:5111-5116, 2000
50. Zmuda JM, Cauley JA, Kuller LH, et al: A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J Bone Miner Res 16:911-917, 2001
51. Haiman CA, Stampfer MG, Giovannucci E, et al: The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 10:743-748, 2001
52. Allen NE, Forrest MS, Key TJ: The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 10:185-189, 2001
53. Ntais C, Polycarpou A, Ioannidis JP: Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12:120-126, 2003
54. Makridakis NM, Ross RK, Pike MC, et al: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354:975-978, 1999
55. Jaffe JM, Malkowicz SB, Walker AH, et al: Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 60:1626-1630, 2000
56. Margiotti K, Sangiuolo F, De Luca A, et al: Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis Markers 16:147-150, 2000
57. Hsing AW, Chen C, Chokkalingam AP, et al: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 10:1077-1082, 2001
58. Mononen N, Ikonen T, Syrjakoski K, et al: A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 84:1344-1347, 2001
59. Shibata A, Garcia MI, Cheng I, et al: Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 52:269-278, 2002
60. Djavan B, Zlotta A, Schulman C, et al: Chemotherapeutic prevention studies of prostate cancer. J Urol 171:510-514, 2004 (2 Pt 2)
61. Devgan SA, Henderson BE, Yu MC, et al: Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 33:9-12, 1997
62. Verreault H, Dufort I, Simard J, et al: Dinucleotide repeat polymorphisms in the HSD3B2 gene. Hum Mol Genet 3:384, 1994
63. Latil AG, Azzouzi R, Cancel GS, et al: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92:1130-1137, 2001
64. Hsing AW, Chokkalingam AP, Gao YT, et al: Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 11:337-341, 2002
65. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004
66. Reichardt JK, Makridakis N, Henderson BE, et al: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55:3973-3975, 1995
67. Gormley GJ, Stoner E, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327:1185-1191, 1992
68. Marberger MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 51:677-686, 1998
69. McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557-563, 1998
70. McConnell JD, Roehrborn CG, Bautista OM, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-2398, 2003
71. Vaughan D, Imperato-McGinley J, McConnell J, et al: Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 60:1040-1044, 2002
72. Lobaccaro JM, Boudon C, Lechevallier E, et al: Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates. Cell Mol Biol (Noisy-le-grand) 42:511-518, 1996
73. Schwartz S Jr, Caceres C, De Torres I, et al: Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. Int J Cancer 76:519-522, 1998
74. Weisser H, Tunn S, Debus M, et al: 5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 59:616-620, 1994
75. Yang XJ, Lecksell K, Short K, et al: Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 53:696-700, 1999
76. Wright AS, Thomas LN, Douglas RC, et al: Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98:2558-2563, 1996
77. REDUCE Study Group: Chemoprevention of prostate cancer in men at high risk: Rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172:1314-1317, 2004
78. Scardino PT: The prevention of prostate cancer-the dilemma continues. N Engl J Med 349:297-299, 2003
79. Bostwick DG, Qian J, Civantos F, et al: Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2:228-235, 2004
80. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate 22:291-299, 1993
81. Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:917-929, 2002
82. Ransohoff DF, McNaughton Collins M, Fowler FJ: Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113:663-667, 2002
83. Lu-Yao G, Albertsen PC, Stanford JL, et al: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325:740, 2002
84. Oliver SE, May MT, Gunnell D: International trends in prostate-cancer mortality in the "PSA ERA." Int J Cancer 92:893-898, 2001
85. Etzioni R, Penson DF, Legler JM, et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981-990, 2002